Heat Biologics Stock Price, News & Analysis (NASDAQ:HTBX)

$3.18 -0.22 (-6.47 %)
(As of 01/23/2018 04:57 AM ET)
Previous Close$3.40
Today's Range$3.01 - $3.69
52-Week Range$3.00 - $12.50
Volume209,700 shs
Average Volume76,145 shs
Market Capitalization$113.54 million
P/E Ratio-0.76
Dividend YieldN/A
Beta0.69

About Heat Biologics (NASDAQ:HTBX)

Heat Biologics logoHeat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Receive HTBX News and Ratings via Email

Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolNASDAQ:HTBX
CUSIPN/A
Phone+1-919-2407133

Debt

Debt-to-Equity RatioN/A
Current Ratio1.98%
Quick Ratio1.98%

Price-To-Earnings

Trailing P/E Ratio-0.762589928057554
Forward P/E Ratio-1.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$340,000.00
Price / Sales334.74
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book11.78

Profitability

Trailing EPS($4.17)
Net Income$-12,570,000.00
Net Margins-1,184.92%
Return on Equity-149.69%
Return on Assets-92.51%

Miscellaneous

Employees19
Outstanding Shares35,790,000

Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

When did Heat Biologics' stock split? How did Heat Biologics' stock split work?

Heat Biologics shares reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

How were Heat Biologics' earnings last quarter?

Heat Biologics, Inc. (NASDAQ:HTBX) released its earnings results on Monday, November, 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.90) by $0.30. The biopharmaceutical company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.50 million. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. View Heat Biologics' Earnings History.

When will Heat Biologics make its next earnings announcement?

Heat Biologics is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for Heat Biologics.

Where is Heat Biologics' stock going? Where will Heat Biologics' stock price be in 2018?

2 analysts have issued 1-year price targets for Heat Biologics' stock. Their predictions range from $22.50 to $22.50. On average, they anticipate Heat Biologics' stock price to reach $22.50 in the next twelve months. View Analyst Ratings for Heat Biologics.

Who are some of Heat Biologics' key competitors?

Who are Heat Biologics' key executives?

Heat Biologics' management team includes the folowing people:

  • Jeffrey Alan Wolf J.D., Chairman of the Board, Chief Executive Officer (Age 53)
  • Timothy J. Creech, Chief Financial Officer (Age 55)
  • Jeff Tobin Hutchins Ph.D., Chief Operating Officer, Chief Scientific Officer (Age 58)
  • Ann A. Rosar, Vice President - Finance, Corporate Secretary (Age 60)
  • Anil K. Goyal Ph.D., Vice President - Business Development (Age 51)
  • John K. A. Prendergast Ph.D., Director (Age 63)
  • Louis C. Bock, Independent Director (Age 52)
  • Michael Kharitonov Ph.D., Independent Director (Age 52)
  • John P. Monahan Ph.D., Independent Director (Age 69)
  • Edward B. Smith III, Independent Director (Age 40)

How do I buy Heat Biologics stock?

Shares of Heat Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heat Biologics' stock price today?

One share of Heat Biologics stock can currently be purchased for approximately $3.18.

How big of a company is Heat Biologics?

Heat Biologics has a market capitalization of $113.54 million and generates $340,000.00 in revenue each year. The biopharmaceutical company earns $-12,570,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Heat Biologics employs 19 workers across the globe.

How can I contact Heat Biologics?

Heat Biologics' mailing address is 801 Capitola Dr, DURHAM, NC 27713-4382, United States. The biopharmaceutical company can be reached via phone at +1-919-2407133 or via email at [email protected]


MarketBeat Community Rating for Heat Biologics (HTBX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  268
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Heat Biologics (NASDAQ:HTBX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.50$22.50$21.25$50.00
Price Target Upside: 320.56% upside320.56% upside297.20% upside8,191.87% upside

Heat Biologics (NASDAQ:HTBX) Consensus Price Target History

Price Target History for Heat Biologics (NASDAQ:HTBX)

Heat Biologics (NASDAQ:HTBX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Griffin SecuritiesInitiated CoverageBuy$22.50HighView Rating Details
7/4/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/8/2016Roth CapitalSet Price TargetBuy$20.00N/AView Rating Details
4/9/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
2/21/2016HC WainwrightReiterated RatingBuy$130.00N/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Heat Biologics (NASDAQ:HTBX) Earnings History and Estimates Chart

Earnings by Quarter for Heat Biologics (NASDAQ:HTBX)

Heat Biologics (NASDAQ HTBX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018($0.07)N/AView Earnings Details
11/13/2017Q3 2017($0.90)($0.60)$0.50 million$0.47 millionViewN/AView Earnings Details
8/14/2017Q2 2017($1.00)($0.90)ViewN/AView Earnings Details
5/11/2017Q1 2017($1.50)($1.20)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.70)($1.20)$0.13 million$0.12 millionViewN/AView Earnings Details
11/10/2016Q3 2016($1.50)($0.80)$0.22 millionViewN/AView Earnings Details
8/15/2016Q2($2.70)($1.70)ViewN/AView Earnings Details
5/11/2016Q1($5.60)($5.00)ViewN/AView Earnings Details
2/18/2016Q4($6.40)($7.80)ViewN/AView Earnings Details
10/30/2015Q3($6.10)($6.20)ViewN/AView Earnings Details
8/13/2015Q2($4.70)($5.60)ViewN/AView Earnings Details
5/14/2015Q1($4.90)($5.70)ViewN/AView Earnings Details
4/16/2015($4.90)($5.60)ViewN/AView Earnings Details
3/27/2015Q4 2014($4.40)($5.60)ViewN/AView Earnings Details
11/14/2014Q314($3.50)($4.60)ViewN/AView Earnings Details
8/14/2014Q214($3.80)($4.40)ViewN/AView Earnings Details
5/13/2014Q1 2014($3.80)($3.60)ViewN/AView Earnings Details
4/1/2014($3.00)($5.50)ViewN/AView Earnings Details
11/14/2013Q3 2013($1.40)($4.80)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Heat Biologics (NASDAQ:HTBX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.07)($0.07)($0.07)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181($0.05)($0.05)($0.05)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Heat Biologics (NASDAQ:HTBX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Heat Biologics (NASDAQ HTBX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.70%
Institutional Ownership Percentage: 7.85%
Insider Trades by Quarter for Heat Biologics (NASDAQ:HTBX)
Institutional Ownership by Quarter for Heat Biologics (NASDAQ:HTBX)

Heat Biologics (NASDAQ HTBX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/23/2016Michael KharitonovDirectorBuy900,000$0.75$675,000.00949,960View SEC Filing  
5/19/2014Jeffrey Alan WolfCEOBuy2,500$4.13$10,325.00View SEC Filing  
5/16/2014Paul BelskyDirectorBuy2,500$4.11$10,275.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Heat Biologics (NASDAQ HTBX) News Headlines

Source:
DateHeadline
Heat latest Triangle biopharma to execute reverse stock splitHeat latest Triangle biopharma to execute reverse stock split
finance.yahoo.com - January 22 at 5:57 PM
Zacks: Heat Biologics, Inc. (HTBX) Given $2.63 Average Price Target by BrokeragesZacks: Heat Biologics, Inc. (HTBX) Given $2.63 Average Price Target by Brokerages
www.americanbankingnews.com - January 20 at 3:38 AM
Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Investors?Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Investors?
finance.yahoo.com - January 2 at 8:59 PM
Heat Biologics, Inc. (HTBX) Short Interest Down 41.6% in NovemberHeat Biologics, Inc. (HTBX) Short Interest Down 41.6% in November
www.americanbankingnews.com - December 16 at 3:42 AM
ETFs with exposure to Heat Biologics, Inc. : December 11, 2017ETFs with exposure to Heat Biologics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:38 PM
Heat Biologics (HTBX) Granted FDA Guidance at Type C Meeting for HS-110 Clinical Trial - StreetInsider.comHeat Biologics (HTBX) Granted FDA Guidance at Type C Meeting for HS-110 Clinical Trial - StreetInsider.com
www.streetinsider.com - December 8 at 11:37 AM
Heat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung CancerHeat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung Cancer
finance.yahoo.com - December 7 at 11:52 AM
Zacks: Analysts Set $8.42 Price Target for Heat Biologics, Inc. (HTBX)Zacks: Analysts Set $8.42 Price Target for Heat Biologics, Inc. (HTBX)
www.americanbankingnews.com - December 5 at 11:30 AM
ETFs with exposure to Heat Biologics, Inc. : November 30, 2017ETFs with exposure to Heat Biologics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:38 PM
Want To Invest In Heat Biologics Inc (HTBX)? Here’s How It Performed LatelyWant To Invest In Heat Biologics Inc (HTBX)? Here’s How It Performed Lately
finance.yahoo.com - November 30 at 12:05 PM
Heat Biologics, Inc. :HTBX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Heat Biologics, Inc. :HTBX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 11:24 AM
Heat Biologics (HTBX) Terminates Rights OfferingHeat Biologics (HTBX) Terminates Rights Offering
www.streetinsider.com - November 23 at 4:50 PM
Heat Biologics (HTBX) Terminates Rights Offering - StreetInsider.comHeat Biologics (HTBX) Terminates Rights Offering - StreetInsider.com
www.streetinsider.com - November 22 at 8:58 PM
Heat Biologics (HTBX) Prices 5.8M Common Stock Offering at $0.43/ShareHeat Biologics (HTBX) Prices 5.8M Common Stock Offering at $0.43/Share
www.streetinsider.com - November 17 at 11:13 PM
Heat Biologics Prices 5,813,950 Shares for Common Stock OfferingHeat Biologics Prices 5,813,950 Shares for Common Stock Offering
finance.yahoo.com - November 17 at 6:08 PM
Here’s What’s Behind Heat Biologics Inc (HTBX) Drop TodayHere’s What’s Behind Heat Biologics Inc (HTBX) Drop Today
finance.yahoo.com - November 17 at 6:08 PM
After-Hours Stock Movers 11/16: (SCVL) (SPLK) (ROST) Higher; (HTBX) (WSM) (VBLT) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 11/16: (SCVL) (SPLK) (ROST) Higher; (HTBX) (WSM) (VBLT) Lower (more...) - StreetInsider.com
www.streetinsider.com - November 17 at 8:01 AM
Heat Biologics (HTBX) Announces Proposed Common Share Offering - StreetInsider.comHeat Biologics (HTBX) Announces Proposed Common Share Offering - StreetInsider.com
www.streetinsider.com - November 17 at 8:01 AM
Heat Biologics (HTBX) Announces Proposed Common Share OfferingHeat Biologics (HTBX) Announces Proposed Common Share Offering
www.streetinsider.com - November 16 at 5:50 PM
Heat Biologics Announces Proposed Public Offering of Common StockHeat Biologics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 16 at 5:50 PM
Is It Time To Buy Heat Biologics Inc (HTBX)?Is It Time To Buy Heat Biologics Inc (HTBX)?
finance.yahoo.com - November 14 at 8:06 PM
Heat Biologics, Inc. (HTBX) Releases Quarterly  Earnings Results, Beats Estimates By $0.03 EPSHeat Biologics, Inc. (HTBX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 14 at 7:18 AM
Heat Biologics Reports Third-quarter 2017 Results and Corporate UpdateHeat Biologics Reports Third-quarter 2017 Results and Corporate Update
finance.yahoo.com - November 13 at 8:56 AM
Heat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual MeetingHeat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
finance.yahoo.com - November 12 at 10:29 AM
Heat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy of Cancer (SITC) Annual MeetingHeat Biologics to Present Data on its ComPACT Technology, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
finance.yahoo.com - November 7 at 2:42 AM
Subsidiary of Heat Biologics (HTBX) Receives Second Tranche of $15.2M CPRIT Grant AwardSubsidiary of Heat Biologics (HTBX) Receives Second Tranche of $15.2M CPRIT Grant Award
www.streetinsider.com - October 31 at 9:10 PM
Subsidiary of Heat Biologics (HTBX) Receives Second Tranche of $15.2M CPRIT Grant Award - StreetInsider.comSubsidiary of Heat Biologics (HTBX) Receives Second Tranche of $15.2M CPRIT Grant Award - StreetInsider.com
www.streetinsider.com - October 30 at 8:58 PM
Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its $15.2 Million CPRIT Grant AwardPelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its $15.2 Million CPRIT Grant Award
finance.yahoo.com - October 30 at 8:57 PM
Heat Biologics Rights Offering Materials Available for Shareholders of RecordHeat Biologics Rights Offering Materials Available for Shareholders of Record
finance.yahoo.com - October 28 at 6:40 AM
Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory BoardsHeat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards
finance.yahoo.com - October 23 at 7:13 PM
Heat Biologics, Inc. (HTBX) Scheduled to Post Earnings on MondayHeat Biologics, Inc. (HTBX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 23 at 1:22 PM
Heat Biologics (HTBX) Presents At 2017 BIO Investor Forum - SlideshowHeat Biologics (HTBX) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 19 at 3:08 AM
Heat Biologics (HTBX) Prices for Rights Offering - StreetInsider.com - StreetInsider.comHeat Biologics (HTBX) Prices for Rights Offering - StreetInsider.com - StreetInsider.com
www.streetinsider.com - October 18 at 1:17 AM
Heat Biologics (HTBX) Prices for Rights OfferingHeat Biologics (HTBX) Prices for Rights Offering
www.streetinsider.com - October 16 at 7:24 PM
Heat Biologics Announces Pricing for Rights Offering to Stockholders and Participating Warrant HoldersHeat Biologics Announces Pricing for Rights Offering to Stockholders and Participating Warrant Holders
finance.yahoo.com - October 16 at 7:24 PM
Heat Biologics, Inc. (HTBX) Sees Significant Decrease in Short InterestHeat Biologics, Inc. (HTBX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 15 at 2:20 AM
UPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San FranciscoUPDATE: Heat Biologics to Present at the Upcoming BIO Investor Forum in San Francisco
finance.yahoo.com - October 13 at 12:16 AM
Before You Buy Heat Biologics Inc’s (HTBX), You Should Consider ThisBefore You Buy Heat Biologics Inc’s (HTBX), You Should Consider This
finance.yahoo.com - October 10 at 7:03 PM
Selexis SA and Pelican Therapeutics Sign Agreement to Advance ... - Business Wire (press release)Selexis SA and Pelican Therapeutics Sign Agreement to Advance ... - Business Wire (press release)
www.businesswire.com - October 4 at 3:32 PM
Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical ProgramsSelexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
finance.yahoo.com - October 4 at 3:32 PM
Heat Biologics (HTBX) Subsidiary Pelican Therapeutics Reports Manufacturing Agreement with KBI Biopharma to ... - StreetInsider.comHeat Biologics (HTBX) Subsidiary Pelican Therapeutics Reports Manufacturing Agreement with KBI Biopharma to ... - StreetInsider.com
www.streetinsider.com - September 27 at 10:28 PM
Griffin Securities Initiates Coverage on Heat Biologics, Inc. (HTBX)Griffin Securities Initiates Coverage on Heat Biologics, Inc. (HTBX)
www.americanbankingnews.com - September 18 at 12:16 AM
Heat Biologics (HTBX) Plans Common Stock Rights Offering - StreetInsider.comHeat Biologics (HTBX) Plans Common Stock Rights Offering - StreetInsider.com
www.streetinsider.com - September 16 at 6:53 PM
Heat Biologics Announces Common Stock Rights Offering in Form S-1 FilingHeat Biologics Announces Common Stock Rights Offering in Form S-1 Filing
finance.yahoo.com - September 16 at 1:09 AM
Heat Biologics, Inc. (HTBX) Forecasted to Earn Q3 2017 Earnings of ($0.09) Per ShareHeat Biologics, Inc. (HTBX) Forecasted to Earn Q3 2017 Earnings of ($0.09) Per Share
www.americanbankingnews.com - September 15 at 7:20 AM
Heat Biologics (HTBX) Granted Type C Meeting with FDA to Discuss ... - StreetInsider.comHeat Biologics (HTBX) Granted Type C Meeting with FDA to Discuss ... - StreetInsider.com
www.streetinsider.com - September 14 at 8:46 PM
Heat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing RequirementsHeat Biologics Granted 180-day Extension by NASDAQ to Regain Compliance with Listing Requirements
finance.yahoo.com - September 14 at 8:46 PM
Heat Biologics (HTBX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowHeat Biologics (HTBX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 6:09 AM
Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung CancerHeat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer
finance.yahoo.com - September 13 at 12:06 AM
Analyzing Heat Biologics (HTBX) and its CompetitorsAnalyzing Heat Biologics (HTBX) and its Competitors
www.americanbankingnews.com - September 12 at 12:30 PM

SEC Filings

Heat Biologics (NASDAQ:HTBX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Heat Biologics (NASDAQ:HTBX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Heat Biologics (NASDAQ HTBX) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.